Acquisition Strengthens Offerings in Intravascular Lithotripsy for Coronary and Peripheral Artery Disease
Boston Scientific (NYSE: BSX) announced a definitive agreement to acquire Bolt Medical, developer of an advanced intravascular lithotripsy (IVL) platform, for $443 million upfront and up to $221 million in milestone payments. This acquisition enhances Boston Scientific’s cardiovascular portfolio, targeting the rapidly growing IVL segment.
Key Highlights
- Strategic Alignment: Bolt’s laser-based IVL platform complements Boston Scientific’s interventional cardiology and peripheral vascular offerings.
- Technology Innovation: The Bolt IVL™ system uses acoustic pressure waves to break up calcium in arteries, improving outcomes for patients with calcified arterial disease.
- Clinical Advancements: Recent pivotal trials for Bolt IVL devices address both Above-the-Knee (ATK) and Below-the-Knee (BTK) applications.
Addressing a Global Health Challenge
- Significant Market Opportunity: Cardiovascular disease remains the leading cause of death worldwide, with calcified arterial lesions complicating treatments.
- Innovative Approach: The Bolt IVL™ system offers a minimally invasive solution designed to enhance treatment precision and reduce procedural risks.
Transaction Details
- Boston Scientific will acquire the remaining 74% stake in Bolt Medical, adding to its existing 26% equity position.
- The acquisition is expected to close in the first half of 2025, subject to customary conditions.
- Financial Impact: The deal is projected to be slightly dilutive to adjusted EPS in 2025 but offset by cost efficiencies.
A Strategic Growth Move
“The addition of Bolt Medical’s innovative platform allows us to address a significant unmet need for patients with calcified arterial disease,” said Lance Bates, SVP of Interventional Cardiology Therapies at Boston Scientific.
Follow MEDWIRE.AI for the latest updates on medical technology innovations and strategic industry developments.
